Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹5,527 Cr
verified against source
Revenue YoY
14%
reported change
EBITDA
₹762 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Apollo Hospitals delivered a strong Q3 FY25 with consolidated revenue of INR 5,527 crore (+14% YoY) and EBITDA of INR 762 crore (+24% YoY). PAT surged 52% YoY to INR 372 crore, driven by mid-teens growth across all segments and margin expansion in healthcare services (24.1% EBITDA margin). The hospital business saw 13% revenue growth, with high-margin CONGO specialties (cardiac, oncology, neuro, gastro, ortho) growing at 10.35% volume, offsetting a 1.5% revenue drag from Bangladesh patient decline. Apollo HealthCo (pharmacy & digital) grew 15% YoY, with digital losses narrowing. Management guided for calibrated bed additions (1,737 beds over FY26-27) with minimal margin impact (~100 bps), and expects Apollo 24/7 to break even by Q2/Q3 FY26. Key risk: slower-than-expected recovery in Bangladesh patient inflows and competitive pressure in digital pharmacy.
Colored figures show movement against the previous available record.
Guidance to track
- Digital platform expected to achieve EBITDA break-even by end of Q2 or Q3 of next fiscal year, with GMV target of INR 900-1,000 crore.
- Healthcare services EBITDA margin expected to remain around 24% next year, with new bed openings impacting margins by no more than 100 bps.
- Pune and Kolkata hospitals to open in H1 FY26; Hyderabad and Gurugram by end of FY26; 50% of 1,737 beds operational in FY26, rest in FY27.
- Apollo HealthCo (including Keimed) targets INR 25,000 crore revenue and 7-8% EBITDA margin by FY27.
Risks flagged
- Bangladesh patient footfall dropped, causing 1.5% revenue impact; management is exploring other international markets but recovery timeline uncertain.
- Analyst raised concerns about high ESOP costs and competition from startups; management acknowledged but defended ESOP as retention tool.
- Large capacity addition (1,737 beds) could pressure margins if occupancy ramps slower than expected; management expects 100 bps margin impact.
Key quotes
- Our results reflect an all-around growth, with all three business segments reporting mid-teens revenue growth.
- We will operate on both levels, but I would request all of you to bear with us for one more quarter.
- We are quite hopeful that we should be able to break even in less than 12 months.
Research modules